Form 4: Avidity Biosciences CSO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, sold 2,373 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, Inc. (RNA), reported a sale of common stock.
• The transaction involved the disposition of 2,373 shares of common stock at a price of $72.23 per share.
• The sale occurred on January 7, 2026, and was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) on January 6, 2026.
• This was a 'sell-to-cover' transaction, mandated by the Issuer's equity incentive plans, and does not represent a discretionary trade by Mr. Flanagan.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following this transaction, Mr. Flanagan beneficially owns 91,627 shares of Avidity Biosciences common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell-to-cover' for tax withholding obligations related to RSU vesting, rather than a discretionary sale reflecting management's view on the company's prospects.

Future Outlook

NA

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs and the sale of the resulting shares of common stock.
• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This Form 4 filing details a routine, non-discretionary insider transaction for tax purposes, which is common practice across all industries for executives receiving equity compensation. It does not provide information related to broader industry trends or competitive positioning.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Stock Sale, Chief Scientific Officer, W. Michael Flanagan, RSU Vesting, Tax Withholding, 10b5-1 Plan